Company Analysis
Sign in

Scinai Immunotherapeutics Ltd. (SCNI)

Nasdaq: SCNI · Biological Products, (No Diagnostic Substances) · Jerusalem, IL · filing with the SEC since 2014
Full chart Alerts Compare
Grade3.9
◀ Past 3.5● Present 3.8▶ Future 4.3
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Report filedApr 1, 2026May 7, 2025May 15, 2024Apr 17, 2023Mar 28, 2022May 13, 2021
Revenue1,311658····
Cost of revenue3,9631,238····
Gross profit-2,652-580····
Research and development2,3695,5325,2105,7653,249·
Selling, general and administrative2,5212,5264,5055,2967,625·
General and administrative···1,5022,434·
Total operating expenses4,8908,0589,70611,06110,862·
Operating income-7,542-8,638-9,706r-11,061-10,862·
Interest expense··343351336·
Interest and investment income7651,3253,2065,2652,656·
Other income (expense), net-359-1,422-3,8015,100496·
Total non-operating income (expense)-765-1,3253,2065,2652,656·
Income from continuing operations···8,1303,152·
Net income-8,3074,796-6,500-5,796-8,206·
Net income to common shareholders··6,500r5,7968,206·
Earnings per share, basic··0.004r0.01r-0.02·
Earnings per share, diluted··0.004r0.01r-0.02·
Weighted average shares, basic9,339,460,9653,225,472,2661,562,627,495754,076,407564,575,967·
Weighted average shares, diluted9,339,460,9653,225,472,2661,562,627,495754,076,407564,575,967·
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:Revenues
Cost of revenue what it cost to make or buy what it soldus-gaap:CostOfRevenue
Gross profit revenue less the cost of what it soldus-gaap:GrossProfit
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative the cost of selling and of running the companyus-gaap:SellingGeneralAndAdministrativeExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest expense what its borrowing costus-gaap:InterestExpense
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeNet
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense
Income from continuing operations profit from the businesses it keepsus-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
SI Assistanton SCNI · research, not advice